Vogenx priced an $81.3 million IPO to fund continued development of mizagliflozin, a glucose control SGLT1 inhibitor in programs spanning post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing’s syndrome. The offering provides near-term capital for trial expansion and manufacturing readiness across multiple metabolic indications. In rare disease funding, Vaderis Therapeutics closed an oversubscribed $152 million Series B to support engasertib (VAD-044) in hereditary hemorrhagic telangiectasia (HHT), including initiation of the global Phase III HEROIC study. The financing is explicitly tied to operations through potential U.S. regulatory approval. Together, the deals highlight investor appetite returning to metabolic and genetically defined programs where mechanism-driven assets face clear, next-step clinical milestones.